Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Retraction: Abdallah MS, Ramadan AN, Omara-Reda H, et al. Double-blind, randomized, placebo-controlled pilot study of the phosphodiesterase-3 inhibitor cilostazol as an adjunctive to antidepressants in patients with major depressive disorder. CNS Neurosci. Ther. 2021;27:1540-1548 (https://doi.org/10.1111/cns.13731) The above article, published online on September 21, 2021 in Wiley Online Library (wileyonlinelibrary.com) has been retracted by agreement between the journal's Editor-in-Chief, Xiaoming Hu, and John Wiley and Sons Ltd. Following publication, multiple concerns were raised by a third party about the integrity of the clinical trial. An investigation revealed significant issues regarding the reliability of the reported data. As a result, the Editor-in-Chief no longer has confidence in the validity of the results presented in this article.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10926050 | PMC |
http://dx.doi.org/10.1111/cns.14667 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!